Prices are updated after-hours
Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
crawled time : 16:20    save search
Junshi Biosciences and Coherus Share Update on the FDA Review of the Biologics License Application (BLA) for Toripalimab as Treatment for Recurrent or Metastatic Nasopharyngeal Carcinoma (NPC)
Published: 2022-12-25 (Crawled : 16:20) - globenewswire.com
CHRS | $2.0 -6.98% -8.04% 1.8M twitter stocktwits trandingview |
Health Technology
 | Email alert Add to watchlist
treatment fda application license review update
Media Statement: Duke Energy curtailing energy load in the Carolinas
Published: 2022-12-24 (Crawled : 16:20) - prnewswire.com
DUK | $95.93 1.51% -0.05% 2.1M twitter stocktwits trandingview |
Utilities
 | Email alert Add to watchlist
media energy
LPI Completes Maricunga Ownership Consolidation
Published: 2022-12-24 (Crawled : 16:20) - globenewswire.com
LTUM | $0.0364 -3.96% 33.16% 230K twitter stocktwits trandingview |
Mining, Quarrying, and Oil and ...
 | Email alert Add to watchlist
BLILF | $0.2164 twitter stocktwits trandingview |
Process Industries
 | Email alert Add to watchlist
How to Maximize Your Loan-to-Value (LTV) Ratio When You Borrow
Published: 2022-12-18 (Crawled : 16:20) - myfw.com
MYFW | News | $13.65 0.36% 49K twitter stocktwits trandingview |
Finance
 | Email alert Add to watchlist
EYEPOINT INVESTOR ALERT
Published: 2022-12-18 (Crawled : 16:20) - prnewswire.com
EYPT | $17.5 -16.43% -19.73% 4.1M twitter stocktwits trandingview |
Health Technology
 | Email alert Add to watchlist
alert
IDT Corporation to Report First Quarter FY2023 Results
Published: 2022-12-17 (Crawled : 16:20) - idt.net
IDT S | $35.93 0.45% 0.0% 54K twitter stocktwits trandingview |
Communications
 | Email alert Add to watchlist
fy2023 report corporation results
IDT Corporation to Present at Sidoti December Small Cap Virtual Investor Conference
Published: 2022-12-17 (Crawled : 16:20) - idt.net
IDT S | $35.93 0.45% 0.0% 54K twitter stocktwits trandingview |
Communications
 | Email alert Add to watchlist
conference corporation
NRS Launches B2B Marketplace
Published: 2022-12-17 (Crawled : 16:20) - idt.net
IDT S | $35.93 0.45% 0.0% 54K twitter stocktwits trandingview |
Communications
 | Email alert Add to watchlist
IDT Corporation Reports First Quarter Fiscal Year 2023 Results
Published: 2022-12-17 (Crawled : 16:20) - idt.net
UBER | News M 0 d | $71.3 -0.89% -0.69% 19M twitter stocktwits trandingview |
Technology Services
 | Email alert Add to watchlist
RFL 4 | $1.71 -3.93% 0.0% 11K twitter stocktwits trandingview |
Finance
 | Email alert Add to watchlist
IDT S | $35.93 0.45% 0.0% 54K twitter stocktwits trandingview |
Communications
 | Email alert Add to watchlist
year corporation results
NRSInsights’ November Retail Same-Store Sales Report
Published: 2022-12-17 (Crawled : 16:20) - idt.net
IDT S | $35.93 0.45% 0.0% 54K twitter stocktwits trandingview |
Communications
 | Email alert Add to watchlist
sales report retail
CANTALOUPE INVESTOR ALERT
Published: 2022-12-11 (Crawled : 16:20) - prnewswire.com
CTLP | $6.17 -1.6% -1.46% 210K twitter stocktwits trandingview |
Manufacturing
 | Email alert Add to watchlist
alert
At COP15, Investors Announce Nature Action 100 to Tackle Nature Loss and Biodiversity Decline
Published: 2022-12-11 (Crawled : 16:20) - prnewswire.com
BNPQF | $68.558 0.88% -13.4% 920 twitter stocktwits trandingview |
Finance
 | Email alert Add to watchlist
BNPQY | $34.61 1.05% -2.68% 100K twitter stocktwits trandingview |
Finance and Insurance
 | Email alert Add to watchlist
cop15 100
Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Avaya To Contact Him Directly To Discuss Their Options
Published: 2022-12-11 (Crawled : 16:20) - prnewswire.com
AVYA | $0.021 1280.95% 0 twitter stocktwits trandingview |
Electronic Technology
 | Email alert Add to watchlist
Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In GrafTech To Contact Him Directly To Discuss Their Options
Published: 2022-12-11 (Crawled : 16:20) - prnewswire.com
EAF | $1.48 -0.67% 7.43% 2.2M twitter stocktwits trandingview |
Producer Manufacturing
 | Email alert Add to watchlist
Pivotal Odronextamab (CD20xCD3) Phase 2 Data in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma Debut at ASH
Published: 2022-12-11 (Crawled : 16:20) - prnewswire.com
SNYNF | News | $92.7 -2.18% 600K twitter stocktwits trandingview |
Health Technology
 | Email alert Add to watchlist
SNY | News | $45.39 -1.56% -1.58% 4.3M twitter stocktwits trandingview |
Health Technology
 | Email alert Add to watchlist
REGN | $893.99 -0.8% -0.84% 450K twitter stocktwits trandingview |
Health Technology
 | Email alert Add to watchlist
cd20 phase 2
Poseida Therapeutics Presents Preclinical Data from P-FVIII-101 Gene Therapy for Hemophilia A at the 64th ASH Annual Meeting & Exposition
Published: 2022-12-11 (Crawled : 16:20) - prnewswire.com
PSTX | News | $2.0 -1.96% -1.75% 520K twitter stocktwits trandingview |
Health Technology
 | Email alert Add to watchlist
fviii-101 preclinical meeting therapeutics therapy
Aptose Announces Updated Clinical Responses, Breadth of Activity, and Safety Across Four Dose Levels of Tuspetinib in Difficult-to-Treat Acute Myeloid Leukemia Populations
Published: 2022-12-11 (Crawled : 16:20) - globenewswire.com
APTO | $1.3 -4.41% -4.62% 62K twitter stocktwits trandingview |
Health Technology
 | Email alert Add to watchlist
leukemia acute myeloid leukemia
Harpoon Therapeutics Presents Updated Interim Results at ASH 2022 for Novel T Cell Engager HPN217 in Relapsed/Refractory Multiple Myeloma
Published: 2022-12-11 (Crawled : 16:20) - globenewswire.com
HARP | $23.01 0.07% 6.6M twitter stocktwits trandingview |
Health Technology
 | Email alert Add to watchlist
hpn217 therapeutics
Bellicum Announces Presentation by UNC at ASH 2022 on Potential Abrogation of iC9 CAR T-Cell Toxicities with Rimiducid
Published: 2022-12-11 (Crawled : 16:20) - globenewswire.com
BLCM | $0.0748 381.28% 6.1K twitter stocktwits trandingview |
Health Technology
 | Email alert Add to watchlist
t-cell presentation potential
Kymera Therapeutics Presents Preclinical Data Demonstrating Activity of KT-253, a Selective Heterobifunctional MDM2 Degrader, in Acute Myeloid Leukemia at the American Society of Hematology Annual Meeting
Published: 2022-12-11 (Crawled : 16:20) - globenewswire.com
KYMR | $35.12 4.03% 3.98% 620K twitter stocktwits trandingview |
Health Technology
 | Email alert Add to watchlist
kt-253 preclinical meeting leukemia therapeutics acute myeloid leukemia
Gainers vs Losers
59% 41%

Top 10 Gainers
AGBA | News | $1.03 157.5% 57.94% 120M twitter stocktwits trandingview |
Finance
ZCMD | $1.45 5.84% 52.1% 2.3M twitter stocktwits trandingview |
Commercial Services
INVO | $1.52 100.0% 51.13% 5M twitter stocktwits trandingview |
Health Technology
ISPC | $0.421 97.65% 49.53% 37M twitter stocktwits trandingview |
Professional, Scientific, and T...
WLGS | News | $0.5 45.65% 470K twitter stocktwits trandingview |

OST | $0.509 23.81% 45.26% 90K twitter stocktwits trandingview |

GDHG | $0.263 21.76% 40.66% 3.1M twitter stocktwits trandingview |

XPON | News | $3.15 63.21% 37.74% 16M twitter stocktwits trandingview |

TIRX | $0.8 65.02% 30.74% 58M twitter stocktwits trandingview |

BNTC | News | $6.82 42.08% 30.64% 3.5M twitter stocktwits trandingview |
Health Technology
Your saved searches
Save your searches and get alerts when important news are released.